Portfolio company
Akribion Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
The company develops RNA-guided nuclease technology for programmable cell depletion to treat cancer and autoimmune diseases for healthcare providers and patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Arda Therapeutics
This biotechnology company develops targeted cell depletion therapies to treat chronic diseases by identifying and removing specific pathogenic cells in patients.
ArsenalBio
The company develops programmable T cell therapies for patients with solid tumours and autoimmune diseases.
Artiva Biotherapeutics
The company develops allogeneic natural killer cell therapies for patients with autoimmune diseases and cancer.
Azalea Therapeutics
The company develops in vivo genome editing therapies to engineer T cells directly inside the body for patients with cancer and autoimmune diseases.
Arcellx
This biotechnology company develops cell therapies to treat patients with cancer and autoimmune diseases.
Orca Bio
This company develops high-precision allogeneic cell therapies to treat patients with blood cancers and autoimmune diseases by replacing diseased immune systems with donor cells.
Accipiter Biosciences
Accipiter Biosciences develops custom-engineered protein therapies using computational design to treat complex diseases like cancer and autoimmune disorders for the healthcare sector.
Excision Biotherapeutics
This biotechnology company develops CRISPR-based gene editing therapies designed to cure chronic viral infectious diseases for patients.
